Anti-tyrosyl-tRNA synthetase Antibody, Non-Fucosylated (BioBet-1456ZP) (CAT#: BioBet-1456ZP) Datasheet

YARS

tyrosyl-tRNA synthetase

Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released C-terminal fragment is an EMAP II-like cytokine.

YARS; tyrosyl-tRNA synthetase; YRS; YTS; TYRRS; CMTDIC; tyrosine--tRNA ligase, cytoplasmic; tyrosyl--tRNA ligase; tyrosine tRNA ligase 1, cytoplasmic; tyrosyl-tRNA synthetase, cytoplasmic

Cytoplasm

Diseases associated with YARS1 include Charcot-Marie-Tooth Disease, Dominant Intermediate C and Charcot-Marie-Tooth Disease.

Its related pathways are tRNA Aminoacylation and Tyrosine metabolism.

Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).

1.Ubiquitination at Lys119, Lys147, Lys197, Lys206, and Lys513 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

3A4

Humanized

Human

The antibody that bind tyrosyl-tRNA synthetases are used in the treatment of conditions that benefit from the modulation of hematopoiesis.

Hematopoiesis

Hematopoiesis